[ad_1]
Ocugen Inc OCGN shares traded marginally larger by 1.22% at $1.66 throughout Wednesday’s after-hours session. The corporate introduced throughout after-hours buying and selling that the Impartial Knowledge and Security Monitoring Board (DSMB) for the OCU400 Section 1/2 medical trial accomplished a evaluation of security knowledge for topics enrolled in Cohort 2 and recommends continuing to enroll topics in Cohort 3.
What Else? Ocugen says the corporate expects to finish Cohort 3 enrollment in fourth-quarter 2022 as deliberate.
“I am more than happy with the progress of the medical trial,” stated David Birch, director of the Retina Basis of the Southwest and major investigator of the examine. “Presently, sufferers with inherited retinal degeneration don’t have anything to handle their situation in the long run. It’s crucial to maintain working towards an answer for these sufferers who at present don’t have any hope.”
Why It Issues: Ocugen says OCU400 medical trial is a Section 1/2 Examine to Assess the Security and Efficacy of OCU400 for Retinitis Pigmentosa Related to NR2E3 (Nuclear Receptor Subfamily 2 Group E Member 3) and RHO (Rhodopsin) Mutations.
OCU400 is a part of Ocugen’s Modifier Gene Remedy Platform—focusing on inherited retinal illness and dry age-related macular degeneration.
See Additionally: What’s Going On With Novavax Shares?
In accordance with knowledge from Benzinga Professional, Ocugen has a 52-week excessive of $17.65 and a 52-week low of $1.55.
[ad_2]
